[go: up one dir, main page]

WO2009124103A3 - Thérapies de combinaison comprenant des antagonistes de récepteur 1 activé par protéase (par1) associés à des antagonistes récepteur 4 activé par protéase (par4) - Google Patents

Thérapies de combinaison comprenant des antagonistes de récepteur 1 activé par protéase (par1) associés à des antagonistes récepteur 4 activé par protéase (par4) Download PDF

Info

Publication number
WO2009124103A3
WO2009124103A3 PCT/US2009/039070 US2009039070W WO2009124103A3 WO 2009124103 A3 WO2009124103 A3 WO 2009124103A3 US 2009039070 W US2009039070 W US 2009039070W WO 2009124103 A3 WO2009124103 A3 WO 2009124103A3
Authority
WO
WIPO (PCT)
Prior art keywords
antagonists
par1
par4
combination therapies
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/039070
Other languages
English (en)
Other versions
WO2009124103A2 (fr
Inventor
Yan Xia
Samuel Chackalamannil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of WO2009124103A2 publication Critical patent/WO2009124103A2/fr
Publication of WO2009124103A3 publication Critical patent/WO2009124103A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique comportant une quantité efficace d’au moins un antagoniste de PAR1, au moins un antagoniste de PAR4, éventuellement, une quantité efficace d’au moins un agent cardiovasculaire, et, éventuellement un support pharmaceutiquement acceptable. La présente invention concerne également l’utilisation de ces compositions pharmaceutiques pour traiter diverses maladies associées à une thrombose.
PCT/US2009/039070 2008-04-02 2009-04-01 Thérapies de combinaison comprenant des antagonistes de récepteur 1 activé par protéase (par1) associés à des antagonistes récepteur 4 activé par protéase (par4) Ceased WO2009124103A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4177008P 2008-04-02 2008-04-02
US61/041,770 2008-04-02

Publications (2)

Publication Number Publication Date
WO2009124103A2 WO2009124103A2 (fr) 2009-10-08
WO2009124103A3 true WO2009124103A3 (fr) 2010-01-14

Family

ID=40844808

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/039070 Ceased WO2009124103A2 (fr) 2008-04-02 2009-04-01 Thérapies de combinaison comprenant des antagonistes de récepteur 1 activé par protéase (par1) associés à des antagonistes récepteur 4 activé par protéase (par4)

Country Status (1)

Country Link
WO (1) WO2009124103A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2558462T3 (pl) 2010-04-16 2015-03-31 Sanofi Sa Pirydylo-winylo-pirazolo-chinoliny jako inhibitory PAR1
WO2011128421A1 (fr) 2010-04-16 2011-10-20 Sanofi Pyridyl-vinyl-pyrroles tricycliques utilisés comme inhibiteurs du par1
WO2014173859A2 (fr) 2013-04-22 2014-10-30 Institut National De La Recherche Agronomique Antagonistes de par4 pour l'utilisation dans le traitement ou la prévention d'infections par le virus de la grippe de type a
TW201738221A (zh) * 2016-04-22 2017-11-01 Jiangsu Tasly Diyi Pharmaceutical Co Ltd 新的喜巴辛類似物、其藥物組合物及其在醫藥中的應用
WO2020205867A1 (fr) 2019-04-02 2020-10-08 Aligos Therapeutics, Inc. Composés ciblant prmt5
CN110407819B (zh) * 2019-08-02 2020-06-26 牡丹江医学院 一种作为预防外科手术并发症的凝血酶受体拮抗剂

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003089428A1 (fr) * 2002-04-16 2003-10-30 Schering Corporation Antagonistes tricycliques du recepteur de thrombine
WO2007075964A2 (fr) * 2005-12-22 2007-07-05 Schering Corporation Antagonistes de recepteur de thrombine en tant que phophylaxie aux complications de derivation cardiopulmonaire
WO2007117621A1 (fr) * 2006-04-06 2007-10-18 Schering Corporation Traitements combines a base d'un antagoniste des recepteurs de la thrombine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003089428A1 (fr) * 2002-04-16 2003-10-30 Schering Corporation Antagonistes tricycliques du recepteur de thrombine
WO2007075964A2 (fr) * 2005-12-22 2007-07-05 Schering Corporation Antagonistes de recepteur de thrombine en tant que phophylaxie aux complications de derivation cardiopulmonaire
WO2007117621A1 (fr) * 2006-04-06 2007-10-18 Schering Corporation Traitements combines a base d'un antagoniste des recepteurs de la thrombine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LEGER A J ET AL: "Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis", CIRCULATION 200603 US, vol. 113, no. 9, March 2006 (2006-03-01), pages 1244 - 1254, XP002537535, ISSN: 0009-7322 *
LEGER A J ET AL: "Protease-activated receptors in cardiovascular diseases", CIRCULATION 200609 US, vol. 114, no. 10, September 2006 (2006-09-01), pages 1070 - 1077, XP002537536, ISSN: 0009-7322 *
WU ET AL: "Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER BV, NL, vol. 546, no. 1-3, 28 September 2006 (2006-09-28), pages 142 - 147, XP005646239, ISSN: 0014-2999 *

Also Published As

Publication number Publication date
WO2009124103A2 (fr) 2009-10-08

Similar Documents

Publication Publication Date Title
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
WO2010127099A3 (fr) Compositions pharmaceutiques comprenant de l'epa et un agent cardiovasculaire et leurs procédés d'utilisation
WO2010039977A3 (fr) Antagonistes d'hétéroaryle des récepteurs de la prostaglandine d2
WO2010054113A3 (fr) Antagonistes de cycloalkane[b]azaindole de récepteurs de la prostaglandine d2
WO2010003127A3 (fr) Antagonistes des récepteurs de la prostaglandine d<sb>2</sb>
WO2009108720A3 (fr) Antagonistes des récepteurs d2 de la prostaglandine
WO2012032209A3 (fr) Composition pharmaceutique pour le traitement de l'oeil sec
WO2010037059A3 (fr) Antagonistes hétéroaryliques des récepteurs de prostaglandine d<sb>2</sb>
WO2009145989A3 (fr) Antagonistes d’aminoalkylphényle de récepteurs de prostaglandine d<sb>2</sb>
WO2010057118A3 (fr) Antagonistes hétérocycliques des récepteurs de la prostaglandine d2
SG10201907588XA (en) Androgen Receptor Modulators And Uses Thereof
WO2009140642A3 (fr) Antagonistes tricycliques de récepteurs de prostaglandine d<sb>2</sb>
WO2009100441A3 (fr) Formulations retard depot formulations
WO2008148074A3 (fr) Inhibiteurs de mtor et methodes de traitement mettant en œuvre ces inhibiteurs
MY154909A (en) Novel thiophene derivatives
MY164730A (en) Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2010085820A3 (fr) Composés tricycliques en tant qu'antagonistes des récepteurs d2 de la prostaglandine
PL2105164T3 (pl) Nowi antagoniści P2X7R i ich zastosowanie
WO2011143457A3 (fr) Compositions et méthodes permettant de traiter ou de prévenir la fibrillation auriculaire
WO2009124103A3 (fr) Thérapies de combinaison comprenant des antagonistes de récepteur 1 activé par protéase (par1) associés à des antagonistes récepteur 4 activé par protéase (par4)
NZ714288A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
WO2009102707A3 (fr) Oxazaphosphorines substituées
WO2010033167A3 (fr) Formulations d'aptamère anti-thrombine et procédés pour les utiliser
WO2009156680A3 (fr) Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition pharmaceutique la contenant et son utilisation dans le traitement des troubles cognitifs
WO2009097973A3 (fr) Imidazopyridazines en tant qu'inhibiteurs de par1, leur production et leur utilisation en tant que médicaments

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09727836

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09727836

Country of ref document: EP

Kind code of ref document: A2